AbbVie's Roche-rivaling blood cancer bispecific gets FDA priority review, triggering Genmab payday

AbbVie and Genmab have glided into Roche’s slipstream in the race to bring a CD3xCD20 bispecific to market, securing FDA priority review and a May decision date—and triggering an $80 million milestone payment in the process.